Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

SUJITH RAO KALMADI

Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology

NPI
1508973447
CMS profile
22736
Location
CHANDLER, AZ

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$236,880.70

390 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

By paying entity

PY2021 · entire year · sorted by reported total

Paying entityAmountRecords
Daiichi Sankyo Inc. $40,829.11 23
Incyte Corporation $34,513.44 42
AstraZeneca Pharmaceuticals LP $34,303.72 41
Janssen Biotech, Inc. $16,386.87 41
Pharmacyclics LLC, An AbbVie Company $14,475.25 20
G1 Therapeutics, Inc. $11,850.00 9
Astellas Pharma US Inc $9,866.69 3
JAZZ PHARMACEUTICALS INC. $9,805.62 7
Amgen Inc. $9,503.90 17
Blueprint Medicines Corporation $5,591.78 4
Celgene Corporation $5,229.47 14
Genentech USA, Inc. $4,776.32 9
Taiho Oncology, Inc. $3,837.50 2
AngioDynamics, Inc. $3,750.00 2
Epizyme, Inc., $3,571.91 7
Regeneron Pharmaceuticals, Inc. $3,275.00 2
Deciphera Pharmaceuticals Inc. $2,500.00 1
Eisai Inc. $2,494.42 4
Kite Pharma, Inc. $2,424.26 14
Lilly USA, LLC $2,300.00 1
Karyopharm Therapeutics Inc. $2,250.00 1
Novocure Inc. $2,250.00 1
PFIZER INC. $2,086.01 15
Takeda Pharmaceuticals U.S.A., Inc. $1,994.37 2
E.R. Squibb & Sons, L.L.C. $1,715.71 24
Coherus Biosciences Inc. $1,350.00 1
Janssen Scientific Affairs, LLC $1,170.00 1
Bayer HealthCare Pharmaceuticals Inc. $678.53 2
Janssen Pharmaceuticals, Inc $450.00 1
Covis Pharma GmBH $400.00 2
Novartis Pharmaceuticals Corporation $326.36 23
Merck Sharp & Dohme Corporation $126.52 8
Gilead Sciences, Inc. $107.05 6
GlaxoSmithKline, LLC. $82.17 4
Regeneron Healthcare Solutions, Inc. $64.78 3
GENZYME CORPORATION $63.30 4
Ipsen Biopharmaceuticals, Inc $61.40 4
Myovant Sciences Inc. $59.48 3
Seagen Inc. $58.43 4
Clovis Oncology, Inc. $53.73 3
Foundation Medicine, Inc. $38.40 1
Rigel Pharmaceuticals, Inc. $35.41 2
PUMA BIOTECHNOLOGY, INC. $34.93 2
ARRAY BIOPHARMA INC $34.86 3
SUN PHARMACEUTICAL INDUSTRIES INC. $21.32 1
Boehringer Ingelheim Pharmaceuticals, Inc. $19.54 1
Aveo Pharmaceuticals, Inc. $14.02 1
EMD Serono, Inc. $13.10 1
Tactile Systems Technology Inc $12.31 1
AbbVie Inc. $11.86 1
Organon LLC $11.85 1

Page 8 of 8; records 351–390 of 390 matching records. This page contains 40 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

SUJITH RAO KALMADI

NPI 1508973447 · CMS profile ID 22736

Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology

CHANDLER, AZ

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 8 of 8; records 351–390 of 390 matching records. This page contains 40 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1508973447?year=2021&recipient=provider&page=8#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
SUJITH RAO KALMADI, NPI 1508973447, CMS profile ID 22736. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 8 of 8; records 351–390 of 390 matching records. This page contains 40 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1508973447?year=2021&recipient=provider&page=8#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). SUJITH RAO KALMADI, NPI 1508973447, CMS profile ID 22736. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 8 of 8; records 351–390 of 390 matching records. This page contains 40 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1508973447?year=2021&recipient=provider&page=8#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
SUJITH RAO KALMADI, NPI 1508973447, CMS profile ID 22736, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 8 of 8; records 351–390 of 390 matching records. This page contains 40 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1508973447?year=2021&recipient=provider&page=8#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

390 matching records · $236,880.70 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 390 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 351–390 of 390.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Kite Pharma, Inc. $14.1403/10/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 844415917 CMS
Kite Pharma, Inc. $2.7903/09/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 844415913 CMS
Amgen Inc. $14.4803/08/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 826540403 CMS
Merck Sharp & Dohme Corporation $15.0503/05/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848369481 CMS
Amgen Inc. $13.4003/03/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 826540401 CMS
E.R. Squibb & Sons, L.L.C. $9.9803/02/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 783580587 CMS
Merck Sharp & Dohme Corporation $16.6703/02/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848320035 CMS
Novartis Pharmaceuticals Corporation $13.8903/02/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 812739403 CMS
Seagen Inc. $15.3303/01/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 832152093 CMS
Novartis Pharmaceuticals Corporation $9.9402/24/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 812739401 CMS
AstraZeneca Pharmaceuticals LP $2,750.0002/22/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 834349973 CMS
Ipsen Biopharmaceuticals, Inc $12.7202/22/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 841908757 CMS
Novartis Pharmaceuticals Corporation $14.2802/22/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 812739405 CMS
Novartis Pharmaceuticals Corporation $10.8802/19/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 812739409 CMS
Amgen Inc. $13.4402/18/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 826440725 CMS
AstraZeneca Pharmaceuticals LP $127.9502/18/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 834322469 CMS
AstraZeneca Pharmaceuticals LP $22.4002/18/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 834344605 CMS
Merck Sharp & Dohme Corporation $14.0302/17/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848501613 CMS
Incyte Corporation $14.8102/16/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 835551263 CMS
Janssen Biotech, Inc. $14.4302/16/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788333793 CMS
GENZYME CORPORATION $16.9302/12/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843531283 CMS
AstraZeneca Pharmaceuticals LP $12.0602/08/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 834339795 CMS
Kite Pharma, Inc. $11.8802/08/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 844415935 CMS
Kite Pharma, Inc. $0.1602/05/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 844415931 CMS
Eisai Inc. $16.9402/01/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 817838965 CMS
Janssen Biotech, Inc. $13.1602/01/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788333791 CMS
Janssen Biotech, Inc. $14.1901/29/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788333789 CMS
Rigel Pharmaceuticals, Inc. $22.0701/28/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 854324581 CMS
Daiichi Sankyo Inc. $2,750.0001/27/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 836241225 CMS
Daiichi Sankyo Inc. $685.0001/22/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 836241063 CMS
Daiichi Sankyo Inc. $13.3201/22/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 836245075 CMS
Janssen Scientific Affairs, LLC $1,170.0001/22/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788333801 CMS
Daiichi Sankyo Inc. $22,091.2501/21/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 836240093 CMS
Daiichi Sankyo Inc. $18.3501/21/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 836245045 CMS
Daiichi Sankyo Inc. $22.4001/21/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 836279703 CMS
Daiichi Sankyo Inc. $92.5401/19/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 836278939 CMS
AstraZeneca Pharmaceuticals LP $18.1401/13/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 834329281 CMS
Pharmacyclics LLC, An AbbVie Company $16.6101/12/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 781011553 CMS
AstraZeneca Pharmaceuticals LP $16.9001/07/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 834340445 CMS
AstraZeneca Pharmaceuticals LP $300.0001/06/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 834335535 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $231,557.93 487
PY2020 $132,147.17 229
PY2021 $236,880.70 390
PY2022 $278,425.38 438
PY2023 $295,584.40 381
PY2024 $142,571.36 301
PY2025 $100,540.60 298

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $1,284,149.49 49
PY2024 Recipient $940.00 1
PY2024 Principal investigator $531,188.02 33
PY2023 Principal investigator $150,515.07 37
PY2022 Principal investigator $428,756.22 82
PY2021 Recipient $1,270.00 2
PY2021 Principal investigator $346,769.79 55
PY2020 Principal investigator $249,314.14 41
PY2019 Principal investigator $311,146.25 45

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

49 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Daiichi Sankyo Inc. $8,413.00 12/24/2025 Non-covered Recipient Entity
Urologic Health Associates
DS1062-A-U304 No dispute reported 06/30/2026 1223387147
Principal investigator 1 Daiichi Sankyo Inc. $21,352.00 12/11/2025 Non-covered Recipient Entity
Urologic Health Associates
DS1062-A-U303 No dispute reported 06/30/2026 1223387165
Principal investigator 1 PFIZER INC. $820.00 12/11/2025 Non-covered Recipient Entity
ADMINISTRATORS OF THE TULANE EDUCAT
A RANDOMIZED OPENLABEL PHASE 3 TRIAL OF TISOTUMAB VEDOTIN VS INVESTIGATORS CHOICE CHEMOTHERAPY IN SECOND OR THIRDLINE RECURRENT OR METASTATIC CERVICAL CANCER No dispute reported 06/30/2026 1228702328
Principal investigator 1 Daiichi Sankyo Inc. $128.00 12/04/2025 Non-covered Recipient Entity
Urologic Health Associates
DS1062-A-U304 No dispute reported 06/30/2026 1223387149
Principal investigator 1 PFIZER INC. $2,542.80 10/28/2025 Non-covered Recipient Entity
Ironwood Physicians PC
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY OF TALAZOPARIB WITH ENZALUTAMIDE IN METASTATIC CASTRATIONRESISTANT PROSTATE CANCER No dispute reported 06/30/2026 1228743533
Principal investigator 1 Daiichi Sankyo Inc. $21,855.72 10/23/2025 Non-covered Recipient Entity
Ironwood Physicians, Pc
DS1062-A-U304 No dispute reported 06/30/2026 1223369846
Principal investigator 1 Daiichi Sankyo Inc. $8,401.00 10/23/2025 Non-covered Recipient Entity
Ironwood Physicians, Pc
DS1062-A-U303 No dispute reported 06/30/2026 1223369858
Principal investigator 1 Daiichi Sankyo Inc. $200.00 10/09/2025 Non-covered Recipient Entity
Ironwood Physicians, Pc
DS1062-A-U304 No dispute reported 06/30/2026 1223369842
Principal investigator 1 Daiichi Sankyo Inc. $946.30 10/09/2025 Non-covered Recipient Entity
Ironwood Physicians, Pc
DS1062-A-U304 No dispute reported 06/30/2026 1223369844
Principal investigator 1 Daiichi Sankyo Inc. $14,480.99 10/09/2025 Non-covered Recipient Entity
Ironwood Physicians, Pc
DS1062-A-U303 No dispute reported 06/30/2026 1223369856
Principal investigator 1 Daiichi Sankyo Inc. $564.00 08/27/2025 Non-covered Recipient Entity
Ironwood Physicians, Pc
DS1062-A-U304 No dispute reported 06/30/2026 1223369836
Principal investigator 1 Daiichi Sankyo Inc. $23,390.00 08/27/2025 Non-covered Recipient Entity
Ironwood Physicians, Pc
DS1062-A-U304 No dispute reported 06/30/2026 1223369840
Principal investigator 1 Daiichi Sankyo Inc. $8,090.00 08/27/2025 Non-covered Recipient Entity
Ironwood Physicians, Pc
DS1062-A-U303 No dispute reported 06/30/2026 1223369852
Principal investigator 1 Daiichi Sankyo Inc. $390.00 08/13/2025 Non-covered Recipient Entity
Ironwood Physicians, Pc
DS1062-A-U304 No dispute reported 06/30/2026 1223369834
Principal investigator 1 Daiichi Sankyo Inc. $6,284.25 08/06/2025 Non-covered Recipient Entity
Ironwood Physicians, Pc
DS1062-A-U304 No dispute reported 06/30/2026 1223369838
Principal investigator 1 Daiichi Sankyo Inc. $18,103.45 08/06/2025 Non-covered Recipient Entity
Ironwood Physicians, Pc
DS1062-A-U303 No dispute reported 06/30/2026 1223369854
Principal investigator 1 PFIZER INC. $1,017.90 07/28/2025 Non-covered Recipient Entity
IRONWOOD PHYSICIANS PC
A PHASE 2 BASKET STUDY OF DISITAMAB VEDOTIN IN ADULT SUBJECTS WITH PREVIOUSLY TREATED LOCALLYADVANCED UNRESECTABLE OR METASTATIC SOLID TUMORS THAT EXPRESS HER2 No dispute reported 06/30/2026 1228787761
Principal investigator 1 Daiichi Sankyo Inc. $14,784.00 07/24/2025 Non-covered Recipient Entity
Ironwood Physicians, Pc
DS1062-A-U303 No dispute reported 06/30/2026 1223369848
Principal investigator 1 Daiichi Sankyo Inc. $8,576.00 07/24/2025 Non-covered Recipient Entity
Ironwood Physicians, Pc
DS1062-A-U303 No dispute reported 06/30/2026 1223369850
Principal investigator 1 Daiichi Sankyo Inc. $4,683.09 06/24/2025 Non-covered Recipient Entity
Urologic Health Associates
DS1062-A-U301 No dispute reported 06/30/2026 1223387137
Principal investigator 1 Daiichi Sankyo Inc. $200.00 06/19/2025 Non-covered Recipient Entity
Urologic Health Associates
DS1062-A-U304 No dispute reported 06/30/2026 1223387143
Principal investigator 1 Daiichi Sankyo Inc. $9,964.00 06/13/2025 Non-covered Recipient Entity
Urologic Health Associates
DS1062-A-U304 No dispute reported 06/30/2026 1223387145
Principal investigator 1 Daiichi Sankyo Inc. $200.00 06/05/2025 Non-covered Recipient Entity
Urologic Health Associates
DS1062-A-U303 No dispute reported 06/30/2026 1223387161
Principal investigator 1 Daiichi Sankyo Inc. $175.00 06/05/2025 Non-covered Recipient Entity
Urologic Health Associates
DS1062-A-U303 No dispute reported 06/30/2026 1223387163
Principal investigator 1 PFIZER INC. $1,017.90 06/02/2025 Non-covered Recipient Entity
IRONWOOD PHYSICIANS PC
A PHASE 2 BASKET STUDY OF DISITAMAB VEDOTIN IN ADULT SUBJECTS WITH PREVIOUSLY TREATED LOCALLYADVANCED UNRESECTABLE OR METASTATIC SOLID TUMORS THAT EXPRESS HER2 No dispute reported 06/30/2026 1228778171
Principal investigator 1 PFIZER INC. $16,949.25 05/05/2025 Non-covered Recipient Entity
IRONWOOD PHYSICIANS PC
A PHASE 2 BASKET STUDY OF DISITAMAB VEDOTIN IN ADULT SUBJECTS WITH PREVIOUSLY TREATED LOCALLYADVANCED UNRESECTABLE OR METASTATIC SOLID TUMORS THAT EXPRESS HER2 No dispute reported 06/30/2026 1228724712
Principal investigator 1 Daiichi Sankyo Inc. $15,311.10 04/24/2025 Non-covered Recipient Entity
Urologic Health Associates
DS1062-A-U303 No dispute reported 06/30/2026 1223387159
Principal investigator 1 PFIZER INC. $810.00 04/21/2025 Non-covered Recipient Entity
IRONWOOD PHYSICIANS PC
A PHASE 2 BASKET STUDY OF DISITAMAB VEDOTIN IN ADULT SUBJECTS WITH PREVIOUSLY TREATED LOCALLYADVANCED UNRESECTABLE OR METASTATIC SOLID TUMORS THAT EXPRESS HER2 No dispute reported 06/30/2026 1228779541
Principal investigator 1 PFIZER INC. $4,896.45 04/14/2025 Non-covered Recipient Entity
IRONWOOD PHYSICIANS PC
A PHASE 2 BASKET STUDY OF DISITAMAB VEDOTIN IN ADULT SUBJECTS WITH PREVIOUSLY TREATED LOCALLYADVANCED UNRESECTABLE OR METASTATIC SOLID TUMORS THAT EXPRESS HER2 No dispute reported 06/30/2026 1228781351
Principal investigator 1 PFIZER INC. $26,954.10 04/14/2025 Non-covered Recipient Entity
IRONWOOD PHYSICIANS PC
A PHASE 2 BASKET STUDY OF DISITAMAB VEDOTIN IN ADULT SUBJECTS WITH PREVIOUSLY TREATED LOCALLYADVANCED UNRESECTABLE OR METASTATIC SOLID TUMORS THAT EXPRESS HER2 No dispute reported 06/30/2026 1228794182
Principal investigator 1 PFIZER INC. $19,014.75 04/14/2025 Non-covered Recipient Entity
IRONWOOD PHYSICIANS PC
A PHASE 2 BASKET STUDY OF DISITAMAB VEDOTIN IN ADULT SUBJECTS WITH PREVIOUSLY TREATED LOCALLYADVANCED UNRESECTABLE OR METASTATIC SOLID TUMORS THAT EXPRESS HER2 No dispute reported 06/30/2026 1228795098
Principal investigator 1 PFIZER INC. $3,029.40 04/14/2025 Non-covered Recipient Entity
IRONWOOD PHYSICIANS PC
A PHASE 2 BASKET STUDY OF DISITAMAB VEDOTIN IN ADULT SUBJECTS WITH PREVIOUSLY TREATED LOCALLYADVANCED UNRESECTABLE OR METASTATIC SOLID TUMORS THAT EXPRESS HER2 No dispute reported 06/30/2026 1228795340
Principal investigator 1 Daiichi Sankyo Inc. $400.00 04/10/2025 Non-covered Recipient Entity
Urologic Health Associates
DS1062-A-U304 No dispute reported 06/30/2026 1223387141
Principal investigator 1 PFIZER INC. $100.00 04/05/2025 Non-covered Recipient Entity
Ironwood Physicians PC
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY OF TALAZOPARIB WITH ENZALUTAMIDE IN METASTATIC CASTRATIONRESISTANT PROSTATE CANCER No dispute reported 06/30/2026 1228796470
Principal investigator 1 Daiichi Sankyo Inc. $34,200.00 04/04/2025 Non-covered Recipient Entity
Urologic Health Associates
DS1062-A-U301 No dispute reported 06/30/2026 1223387135
Principal investigator 1 Daiichi Sankyo Inc. $9,050.00 04/04/2025 Non-covered Recipient Entity
Urologic Health Associates
DS1062-A-U303 No dispute reported 06/30/2026 1223387157
Principal investigator 1 PFIZER INC. $5,316.30 03/31/2025 Non-covered Recipient Entity
IRONWOOD PHYSICIANS PC
A PHASE 2 BASKET STUDY OF DISITAMAB VEDOTIN IN ADULT SUBJECTS WITH PREVIOUSLY TREATED LOCALLYADVANCED UNRESECTABLE OR METASTATIC SOLID TUMORS THAT EXPRESS HER2 No dispute reported 06/30/2026 1228779095
Principal investigator 1 Daiichi Sankyo Inc. $7,749.00 03/06/2025 Non-covered Recipient Entity
Urologic Health Associates
DS1062-A-U303 No dispute reported 06/30/2026 1223387153
Principal investigator 1 Daiichi Sankyo Inc. $200.00 03/06/2025 Non-covered Recipient Entity
Urologic Health Associates
DS1062-A-U303 No dispute reported 06/30/2026 1223387155
Principal investigator 1 PFIZER INC. $405.00 02/25/2025 Non-covered Recipient Entity
IRONWOOD PHYSICIANS PC
A PHASE 2 BASKET STUDY OF DISITAMAB VEDOTIN IN ADULT SUBJECTS WITH PREVIOUSLY TREATED LOCALLYADVANCED UNRESECTABLE OR METASTATIC SOLID TUMORS THAT EXPRESS HER2 No dispute reported 06/30/2026 1228789633
Principal investigator 1 Daiichi Sankyo Inc. $1,262.00 02/20/2025 Non-covered Recipient Entity
Urologic Health Associates
DS1062-A-U304 No dispute reported 06/30/2026 1223387129
Principal investigator 1 Daiichi Sankyo Inc. $24,048.00 02/13/2025 Non-covered Recipient Entity
Urologic Health Associates
DS1062-A-U303 No dispute reported 06/30/2026 1223387131
Principal investigator 1 Daiichi Sankyo Inc. $9,009.30 02/13/2025 Non-covered Recipient Entity
Urologic Health Associates
DS1062-A-U303 No dispute reported 06/30/2026 1223387133
Principal investigator 1 Genentech, Inc. $3,150.00 02/04/2025 Non-covered Recipient Entity
IRONWOOD CANCER & RESEARCH CENTERS IRONWOOD PHYSICIANS PC
Phase III Ipatasertib plus abiraterone in mCRPC 1st Line No dispute reported 06/30/2026 1211617634
Principal investigator 1 PFIZER INC. $1,957.50 02/03/2025 Non-covered Recipient Entity
IRONWOOD PHYSICIANS PC
A PHASE 2 BASKET STUDY OF DISITAMAB VEDOTIN IN ADULT SUBJECTS WITH PREVIOUSLY TREATED LOCALLYADVANCED UNRESECTABLE OR METASTATIC SOLID TUMORS THAT EXPRESS HER2 No dispute reported 06/30/2026 1228719775
Principal investigator 1 AstraZeneca UK Limited $750,532.90 01/31/2025 Non-covered Recipient Entity
IRONWOOD CANCER AND RESEARCH CENTER CHANDLER I
CAMBRIA-1 A Phase III, Open-Label,Randomised Study to Assess the Efficacy and Safety of Extended Therapy with Camizestrant (AZD9833, a Next Generation, Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) in Patients with ER+/HER2 No dispute reported 06/30/2026 1185540243
Principal investigator 1 Daiichi Sankyo Inc. $11,134.48 01/16/2025 Non-covered Recipient Entity
Urologic Health Associates
DS1062-A-U304 No dispute reported 06/30/2026 1223387139
Principal investigator 1 Daiichi Sankyo Inc. $14,151.20 01/16/2025 Non-covered Recipient Entity
Urologic Health Associates
DS1062-A-U303 No dispute reported 06/30/2026 1223387151
Principal investigator 1 AstraZeneca Pharmaceuticals LP $147,939.36 01/03/2025 Non-covered Recipient Entity
IRONWOOD CANCER AND RESEARCH CENTER CHANDLER I
This is a Phase III, randomised, double-blind, placebo-controlled, multicentre, international study assessing the efficacy and safety of durvalumab MEDI4736 and domvanalimab AB154 compared with durvalumab plus placebo in adults with locally advanced Stage III No dispute reported 06/30/2026 1185540245

Ownership and Investment Interests

One row per program year and measure, newest year first · the amount invested and the value of the interest are never added together

Program yearMeasureAmountRecords
PY2024 Amount invested $0.00 2
PY2024 Value of interest $7,150.00 2
PY2023 Amount invested $7,000.00 2
PY2023 Value of interest $7,650.00 2
PY2022 Amount invested $650.00 1
PY2022 Value of interest $650.00 1

Ownership and Investment Interests are a separate CMS dataset, shown here separately and never added to payments.

Ownership and investment interests are reported as the value of an interest held, not as a payment received. They are a different measure from the payment total on this page and are never combined with it.

Ownership and Investment Interests records

Ordering applied by this site (program year, newest first, then company) · record values are shown as CMS published them

5 records · PY2022–2024

Ownership and Investment Interests records (CSV)

Program yearCompanyAmount invested Value of interestTerms of interestInterest held by Dispute statusPublishedRecord ID
PY2024 Cornerstone Specialty Network LLC $0.00 $650.00 Common Stock Physician Covered Recipient No dispute reported 06/30/2026 1126328607
PY2024 Cornerstone Specialty Network LLC $0.00 $6,500.00 Common Stock Physician Covered Recipient No dispute reported 06/30/2026 1126328609
PY2023 Cornerstone Specialty Network LLC $0.00 $650.00 Common Stock Physician Covered Recipient No dispute reported 06/30/2026 1022148873
PY2023 Cornerstone Specialty Network LLC $7,000.00 $7,000.00 Common Stock Physician Covered Recipient No dispute reported 06/30/2026 1022148879
PY2022 Cornerstone Specialty Network LLC $650.00 $650.00 Common Stock Physician Covered Recipient No dispute reported 06/30/2026 923382953